OCX — Oncocyte Cashflow Statement
0.000.00%
Last trade - 00:00- $86.51m
- $78.81m
- $1.88m
Annual cashflow statement for Oncocyte, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -29.9 | -64.1 | -72.9 | -27.8 | -60.7 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 4.41 | 35.4 | 24.1 | 6.75 | 39.7 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.399 | -2.2 | -1.94 | -3.97 | -1.32 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -26 | -35.9 | -45.6 | -23.3 | -20.7 |
| Capital Expenditures | -1.23 | -2.25 | -4.34 | -0.281 | -0.516 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -10.5 | -11.7 | 0 | -0.651 | 0.004 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -11.7 | -14 | -4.34 | -0.932 | -0.512 |
| Financing Cash Flow Items | -0.132 | -3.06 | -0.483 | -0.427 | -1.79 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 22.8 | 78.4 | 35.8 | 12.2 | 20.4 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -14.9 | 28.5 | -14.1 | -12.1 | -0.796 |